MedTrace Logo

Drug-Drug Interaction (DDI) Study in Healthy Volunteers

NCT04814498 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-05-17

No results posted yet for this study

Summary

A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers

Conditions

  • Drug Drug Interaction

Interventions

DRUG

Geneva Cocktail

Fixed sequence use of drug cocktail

DRUG

BLD-0409

Fixed sequence use of active product

Sponsors & Collaborators

  • Blade Therapeutics

    lead INDUSTRY

Principal Investigators

  • Kristi McLendon, MD · Nucleus Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2021-09-17
Completion
2022-01-11

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814498 on ClinicalTrials.gov